Cargando…

Calcipotriol/Betamethasone Dipropionate Foam Inhibits Th17 Cytokine Secretion and Improves Epidermal Barrier Markers in a Human Th17 Skin Inflammation Model

INTRODUCTION: T-helper 17 (Th17) cytokines play a key role in the pathophysiology of psoriasis by driving inflammatory responses that lead to epidermal alterations. Markers of epidermal differentiation, including the proteins loricrin (LOR), filaggrin (FLG) and involucrin (IVL), are dysregulated in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lovato, Paola, Jiang, Li, Hebsgaard, Josephine, Ewald, David A., Norsgaard, Hanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859006/ https://www.ncbi.nlm.nih.gov/pubmed/33458806 http://dx.doi.org/10.1007/s13555-020-00482-9

Ejemplares similares

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis
por: Anderko, Marian, et al.
Publicado: (2019)

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis
por: Queille-Roussel, Catherine, et al.
Publicado: (2016)

Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris
por: Vakirlis, Efstratios, et al.
Publicado: (2008)

Efficacy and Safety of Different Formulations of Calcipotriol/Betamethasone Dipropionate in Psoriasis: Gel, Foam, and Ointment
por: Rudnicka, Lidia, et al.
Publicado: (2021)

Editorial: fixed‐dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis
por: Lebwohl, M., et al.
Publicado: (2021)

Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature
por: Pinter, Andreas, et al.
Publicado: (2018)

Development and characterization of a human Th17‐driven ex vivo skin inflammation model
por: Jardet, Claire, et al.
Publicado: (2020)

Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age*
por: Gooderham, M, et al.
Publicado: (2014)

Efficacy of an Innovative Aerosol Foam Formulation of Fixed Combination Calcipotriol plus Betamethasone Dipropionate in Patients with Psoriasis Vulgaris
por: Queille-Roussel, Catherine, et al.
Publicado: (2015)

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam is Effective, Independent of Body Mass Index and the Extent and Severity of Psoriasis
por: Stein Gold, Linda, et al.
Publicado: (2016)

Real-World Experience Using Topical Therapy—Calcipotriol and Betamethasone Dipropionate Foam in Adults with Beyond-Mild Psoriasis
por: Aschoff, Roland, et al.
Publicado: (2021)

Beyond-Mild Psoriasis: A Consensus Statement on Calcipotriol and Betamethasone Dipropionate Foam for the Topical Treatment of Adult Patients
por: Aschoff, Roland, et al.
Publicado: (2021)

Efficacy of calcipotriol plus betamethasone dipropionate foam on psoriatic skin lesions beyond human eyes: An observational study
por: Anna, Campanati, et al.
Publicado: (2022)

Efficacy and Safety of Calcipotriol/Betamethasone Dipropionate Ointment for the Treatment of Trachyonychia: An Open-Label Study
por: Park, Jung-Min, et al.
Publicado: (2015)

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
por: Paul, Carle, et al.
Publicado: (2017)

Early efficacy and safety data with fixed‐dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency
por: Tada, Y., et al.
Publicado: (2021)

Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy
por: Norsgaard, Hanne, et al.
Publicado: (2014)

Supersaturation of Calcipotriene and Betamethasone Dipropionate in a Novel Aerosol Foam Formulation for Topical Treatment of Psoriasis Provides Enhanced Bioavailability of the Active Ingredients
por: Lind, Marianne, et al.
Publicado: (2016)

Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments
por: Queille‐Roussel, C., et al.
Publicado: (2016)

Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real‐life multicenter prospective observational cohort study
por: Campanati, Anna, et al.
Publicado: (2021)

Patient satisfaction and efficacy of calcipotriol plus betamethasone dipropionate gel in plaque psoriasis patients with poor adherence
por: Takahashi, Hidetoshi, et al.
Publicado: (2020)

Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review
por: Torres, Tiago, et al.
Publicado: (2023)

Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO‐ABLE study
por: Paul, C., et al.
Publicado: (2016)

Fixed‐dose combination calcipotriol/betamethasone dipropionate foam provides a rapid onset of action, effective itch relief and improves patient quality of life
por: Jalili, A., et al.
Publicado: (2021)

Efficacy of Calcipotriol/Betamethasone Dipropionate Fixed-Combination Aerosol Foam in the Treatment of Localized Scalp Psoriasis: A Real-Life Case Series from Switzerland
por: Régnier, Antonia, et al.
Publicado: (2022)

Long‐term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach
por: De Simone, Clara, et al.
Publicado: (2022)

Improvement of health-related quality of life and adherence to treatment with calcipotriol-betamethasone dipropionate gel in patients with psoriasis vulgaris
por: Kontochristopoulos, George, et al.
Publicado: (2016)

Calcipotriol and betamethasone dipropionate synergistically enhances the balance between regulatory and proinflammatory T cells in a murine psoriasis model
por: Satake, Kyosuke, et al.
Publicado: (2019)

Signalling of multiple interleukin (IL)‐17 family cytokines via IL‐17 receptor A drives psoriasis‐related inflammatory pathways
por: Tollenaere, M.A.X., et al.
Publicado: (2021)

Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
por: Navarro-Triviño, Francisco José, et al.
Publicado: (2021)

Calcipotriol/betamethasone foam for proactive management of plaque psoriasis: four case reports
por: Apalla, Zoe, et al.
Publicado: (2022)

Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation
por: Colombo, Giorgio L, et al.
Publicado: (2012)

The Effect of the Long-Term Calcipotriol/Betamethasone Dipropionate Local Therapy on Tissue Resident Memory Cells Markers in Psoriatic Eruptions
por: Kasprowicz-Furmańczyk, Marta, et al.
Publicado: (2022)

Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5–15% and PGA ≥ 3: Post-Hoc Analysis From Three Randomized Controlled Trials
por: Iversen, Lars, et al.
Publicado: (2020)

Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching‐adjusted indirect comparison
por: Bewley, A.P., et al.
Publicado: (2019)

Short Term and Long-Term Efficacy of Calcipotriene/ Betamethasone Dipropionate Foam Combination
por: Jalili, Ahmad, et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis
por: Adam, David N., et al.
Publicado: (2022)

Kinetics of Thermal Degradation of Betamethasone Valerate and Betamethasone Dipropionate in Different Media
por: Khattak, S. U. R., et al.
Publicado: (2012)

Betamethasone valerate dressing is non-inferior to calcipotriol–betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial
por: Ortonne, J-P, et al.
Publicado: (2014)

Comparing the Efficacy of Triamcinolone Acetonide Iontophoresis versus Topical Calcipotriol/Betamethasone Dipropionate in Treating Nail Psoriasis: A Bilateral Controlled Clinical Trial
por: Saki, Nasrin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qal88vqqif263buknrrdr3sn82